Akorn Inc (AKRX.O) Key Developments | Reuters.com
Edition:
United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

28.63USD
29 Jun 2016
Change (% chg)

$0.61 (+2.18%)
Prev Close
$28.02
Open
$28.48
Day's High
$28.87
Day's Low
$27.95
Volume
933,477
Avg. Vol
1,975,355
52-wk High
$47.35
52-wk Low
$17.57

Latest Key Developments (Source: Significant Developments)

Akorn Q1 earnings $0.34/shr
Monday, 16 May 2016 04:43pm EDT 

Akorn Inc :Qtrly gaap eps of $0.34.  Full Article

Akorn affirms 2016 net revenue and EPS guidance
Tuesday, 10 May 2016 06:55am EDT 

Akorn Inc : Akorn completes 2014 financial statement restatement and reports audited 2015 and restated 2014 results . Affirms 2016 net revenue and earnings per share guidance .Announced plans to hold its 2016 annual meeting of shareholders on July 1, 2016.  Full Article

Akorn to file annual report for year ended Dec 31, 2015 on May 9
Friday, 6 May 2016 02:50pm EDT 

Akorn Inc :On Monday, May 9, 2016, company plans to file annual report on form 10-K for year ended December 31, 2015.  Full Article

Akorn Appoints Duane A. Portwood as Chief Financial Officer
Tuesday, 13 Oct 2015 05:00pm EDT 

Akorn, Inc:Says Duane A. Portwood, will join Akorn as Executive Vice President and Chief Financial Officer, effective October 30, 2015.Interim Chief Financial Officer Randall Pollard will continue to serve as Senior Vice President, Chief Accounting Officer and Corporate Controller after Portwood's appointment.  Full Article

Akorn Inc Launches Doxercalciferol Injection
Monday, 21 Sep 2015 07:00am EDT 

Akorn Inc:Says It has launched Doxercalciferol Injection Solution, 4 mcg/2 mL in 2mL single-use vials. The launch follows an approval of an abbreviated new drug application for the product from the U.S. Food and Drug Administration on May 7, 2015.  Full Article

Akorn Inc appoints Randy Pollard as Interim Chief Financial Officer
Tuesday, 4 Aug 2015 02:35pm EDT 

Akorn Inc:Announced the appointment of Randall Pollard as Chief Accounting Officer and Interim Chief Financial Officer.Pollard's appointment follows the departure of Timothy Dick, who has elected to step down as Senior Vice President and Chief Financial Officer to pursue other opportunities.  Full Article

Akorn Inc reaffirms FY 2015 guidance
Tuesday, 10 Mar 2015 09:08am EDT 

Akorn Inc:Reaffirms its FY 2015 EPS metrics issued on Feb. 26, 2015 calling for revenue of between $960 million and $980 million and adjusted diluted earnings per share (EPS) of between $1.88 and $1.98.FY 2015 revenue of $970 million and EPS of $1.97 - Thomson Reuters I/B/E/S.  Full Article

Akorn Inc. gives FY 2015 guidance above analysts' estimates
Thursday, 26 Feb 2015 07:00am EST 

Akorn Inc:Expects FY 2015 net revenue between $960-$980 mln.Expects FY 2015 non-GAAP adjusted diluted EPS to be between $1.88-$1.98.Expects FY 2015 GAAP net income of $179-$192 mln.Expects FY 2015 adjusted net income of $239-$251 mln.Expects FY 2015 adjusted EBITDA of $230-$240 mln.FY 2015 revenue of $910 mln, net income of $227 mln and EPS of $1.82 - Thomson Reuters I/B/E/S.  Full Article

Akorn Inc receives FDA approval for Phenylephrine HCl Ophthalmic Solution
Tuesday, 20 Jan 2015 07:00am EST 

Akorn Inc:Has received approval from U.S. FDA on company's New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP, 2.5 pct and 10 pct.Intends to re-launch product shortly.  Full Article

Akorn Inc files new drug application with FDA
Thursday, 15 Jan 2015 05:30pm EST 

Akorn Inc:Confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market difluprednate ophthalmic emulsion 0.05 pct.If approved, Akorn's ANDA product would be a generic version of Alcon's Durezol, which is a topical corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery as well as the treatment of endogenous anterior uveitis.  Full Article

BRIEF-Akorn Q1 earnings $0.34/shr

* Qtrly gaap eps of $0.34 Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)